Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Elixxer Ltd V.ELXR


Primary Symbol: V.ELXR.H Alternate Symbol(s):  ELIXF

Elixxer Ltd. is a Canada-based investment company. The Company has investments and activities in the legal cannabis sector. The Company is focused on investing opportunities in various sectors, with a priority on growth companies that are past the start-up phase.


TSXV:ELXR.H - Post by User

<< Previous
Bullboard Posts
Next >>
Post by SuperMoneyon Jul 20, 2020 6:13am
162 Views
Post# 31289186

News out

News out

https://web.tmxmoney.com/article.php?newsid=4783696859365154&qm_symbol=ELXR

Little Green Pharma achieves key milestone in commercial strategy

 

Highlights:

  • - LGP granted ODC Medical Cannabis Cultivation and Production Permit for its expanded cultivation and manufacturing facility in Australia.
  •  
  • - Expanded Cultivation and manufacturing facility now fully permitted with increased plantings to begin immediately.
  •  
  • - Expanded facility capable of producing sufficient cannabis flower to manufacture 110,000 bottles of medical cannabis oil per annum.
  •  
  • - Permit represents milestone in the Company’s strategy to become a major supplier to Germany, UK and other key European markets.

 

MONTREAL, July 20, 2020 (GLOBE NEWSWIRE) -- Elixxer Ltd. (TSX-V: ELXR)  (OTC-QB: ELIXF) (FRA: 2LQA) (“ELIXXER” or (the “Company”) is pleased to update that its pharmaceutical medical cannabis partner, Little Green Pharma (ASX:LGP) of Australia, has been granted its Medical Cannabis Cultivation and Production Permit (“Permit”) by the Office of Drug Control (“ODC”) for its expanded cultivation and manufacturing facility (“Expanded Facility”).  The grant of the permit means the Expanded Facility is now fully ODC licensed and permitted.

LGP’s Expanded Facility comprises of nine flowering rooms equipped with a number of automated technologies to enhance cultivation effectiveness (including rolling benches, computer-timed LED lighting, climate control and irrigation control), two mother plant rooms and two vegetation rooms.

The Expanded Facility increases the scale of LGP’s cannabis flower production sufficient to manufacture more than 110,000 bottles of medical cannabis oil per annum.  This enhanced capacity is in addition to the Company’s well established third party flower and resin supply lines and will help ensure LGP can meet its growing demand requirements. 

The grant represents the achievement of a key milestone in LGP’s strategy of continued medicinal cannabis sales growth in Australia as it positions itself to become a major supplier into Germany, UK and other key markets in Europe.

The term of the Permit is until March 10th, 2021 in alignment with LGP’s Medicinal Cannabis and Manufacturing licenses.  ODC permits are typically renewed annually or biennially on a rolling bases.

LGP Managing Director Fleta Solomon said:

“The completion of permitting and commencement of significantly increased operations at our expanded cultivation and manufacturing facility represents the achievement of a major milestone for Little Green Pharma.  We expect the increased production scale will allow us to fulfill both growing demand in Australia as well as serve as a platform to become a significant supplier to German, UK and other key European Markets.”  

 


<< Previous
Bullboard Posts
Next >>